SCHEMBL814158

SCHEMBL814158

O=[C]OC1C2CC3CC(C2)CC1C3

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.35
EPHX1 P07099 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11909733 0.70 HSD11B1 (0.31) HSD11B1
SCHEMBL39976 0.67 CYP2C9 (0.42) HSD11B1EPHX1CYP2C9
SCHEMBL16593662 0.66
Lithium SCHEMBL5510213 0.65 CYP2C9 (0.40) HSD11B1EPHX1CYP2C9
SCHEMBL343777 0.65 ATM (0.43)
SCHEMBL7491232 0.65
SCHEMBL4910786 0.63 EPHX1 (0.37) HSD11B1EPHX1CYP2C9
SCHEMBL6862681 0.63 HSD11B1 (0.35) HSD11B1EPHX1CYP2C9
SCHEMBL1048761 0.63 HSD11B1 (0.35) HSD11B1EPHX1CYP2C9
SCHEMBL10584202 0.63 CYP2C9 (0.38) HSD11B1EPHX1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024110477-A2 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-05-30 WO claimed
CN-111875607-A Preparation method of chiral pyrrolopyrimidine compound 正大天晴药业集团股份有限公司 2020-11-03 CN claimed
CN-108699063-B Synthesis process of luccotinib 正大天晴药业集团股份有限公司 2020-06-26 CN claimed
US-9908888-B2 Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines INCYTE CORPORATION (US) 2018-03-06 US claimed
EP-2663309-B1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES INFINITY PHARMACEUTICALS INC (US) 2017-03-15 EP claimed
CN-103648499-B Processes for preparing isoquinolinones and solid forms of isoquinolinones 无限药品股份有限公司 2017-02-15 CN claimed
US-20160152619-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES HCR COLLATERAL MANAGEMENT, LLC 2016-06-02 US claimed
US-9290497-B2 Processes for preparing isoquinolinones and solid forms of isoquinolinones INFINITY PHARMACEUTICALS, INC. (US) 2016-03-22 US claimed
US-20140371450-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES HCR COLLATERAL MANAGEMENT, LLC 2014-12-18 US claimed
EP-2663309-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES Infinity Pharmaceuticals, Inc. (US) 2013-11-20 EP claimed
WO-2012145932-A1 A NOVEL PROCESS FOR THE PREPARATION OF PERAMIVIR AND INTERMEDIATES THEREOF PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) 2012-11-01 WO claimed
US-20120184568-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES HCR COLLATERAL MANAGEMENT, LLC 2012-07-19 US claimed
WO-2012097000-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES REN PINGDA (US) 2012-07-19 WO claimed
US-5449778-A Peptide intermediates WARNER-LAMBERT COMPANY (US) 1995-09-12 US claimed
EP-0637305-A1 NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF WARNER-LAMBERT COMPANY (US) 1995-02-08 EP claimed
US-5264577-A Cyclic amino acids and derivatives thereof WARNER-LAMBERT COMPANY (US) 1993-11-23 US claimed
WO-1993021176-A1 NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF WARNER-LAMBERT COMPANY (US) 1993-10-28 WO claimed
US-20240218014-A1 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-07-04 US disclosed
WO-1993021176-A1 NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF WARNER-LAMBERT COMPANY (US) 1993-10-28 WO disclosed
WO-1992011284-A1 TETRAPEPTIDE DERIVATIVES AND ANALOGUES THE JAMES BLACK FOUNDATION LIMITED (GB) 1992-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218014-A1 SYNTHESIS OF A CYCLIC PEPTIDE VIP, QPCT, PTMS HSD11B1 2178/4885EPHX1 3797/4885CYP2C9 2942/4885
US-20160152619-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES PIK3CA, PIK3CD, PDPK1 HSD11B1 1202/4885EPHX1 2852/4885CYP2C9 627/4885
US-20120184568-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES PIK3CA, PDPK1, AKT3 HSD11B1 1117/4885EPHX1 2842/4885CYP2C9 778/4885
US-20140371450-A1 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES PIK3CA, PDPK1, AKT3 HSD11B1 1117/4885EPHX1 2842/4885CYP2C9 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.